ClinicaliQ Trial Snapshot
- A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Active Not Recruiting • Phase I • NCT06425991.
- Trial comparing two manufacturing methods of teclistamab to ensure the new process produces equivalent drug with same effectiveness in multiple myeloma.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change). Conditions: Multiple Myeloma Interventions: Teclistamab Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 108 participants